PA tag NZ-1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PA tag mAb NZ-1; rat IgG2a, lambda |
PAtag: GVAMPGAEDDVV; 12 amino acid; trademark: No. 5671624; ref: Nature; Nature; Commu biol | Purification, IP, IHC, WB, FACS | PEP2014;
JCS2016 PS2019; AC2021 Sci2022 |
done | APRO |
anti-PA tag mAb NZ-27; human IgG1, lambda |
PAtag: GVAMPGAEDDVV; 12 amino acid; trademark: No. 5671624; from AMED_PDIS project | Purification, IP, IHC, WB, FACS | JBC2023 | done |
|
anti-PA14 tag mAb NZ-1; rat IgG2a, lambda |
PA14 tag: EGGVAMPGAEDDVV; from AMED_SentanBio | Purification, IP, IHC, WB, FACS |
PA14 tag system hGH-fusion Fab |
done |
APRO |
anti-PA16 tag mAb NZ-1; rat IgG2a, lambda |
PA16 tag: GLEGGVAMPGAEDDVV; from AMED_SentanBio | Purification, IP, IHC, WB, FACS | C44Mab5; PMab202; PMab210; PMab213; PMab219; PMab233 | done | APRO |
MAP tag PMab-1 | Character | Application | Ref | Gene cloning | Company |
anti-MAP tag mAb PMab-1: rat IgG2a, kappa--> PAtag |
MAPtag (GDGMVPPGIEDK; 12 amino acids); trademark: No. 5988384; from AMED_KakushinBio; press release | Purification, IP, IHC, WB, FACS | MAB2016 BBREP2018 JB2020 |
done | APRO; AA; abcam; Nov; Merck; BL |
anti-MAP16 tag mAb (PMab-1; rat IgG2a, kappa) |
MAP16 tag: PGTGDGMVPPGIEDKI; 16 amino acids; from AMED_Tousa | Purification, IP, IHC, WB, FACS | PMab-235
PMab-44_goat |
done | |
RAP tag PMab-2 | Character | Application | Ref | Gene cloning | Company |
anti-RAP tag mAb (PMab-2; mouse IgG1, kappa)--> PAtag |
RAP tag: DMVNPGLEDRIE; 12 amino acids; from AMED_KakushinBio | Purification, IP, IHC, WB, FACS | MAB2017 FPS2020 PP2021 |
done |
APRO;
AA;
abcam Merck; BL |
anti-RAP14 tag mAb (double tag) (PMab-2; LpMab-7) |
RAP14 tag (DMVNPGLEDRIEDL; 14 amino acids); from AMED_Tousa | Purification, IP, IHC, WB, FACS | PMab44; PMab256; PDF; PMab253 | done | |
anti-RAP16 tag mAb (PMab-2; mouse IgG1, kappa) |
RAP16 (GPGDDMVNPGLEDRIE; 16 amino acids); from AMED_SentanBio | Purification, IP, IHC, WB, FACS | PMab-225_alpaca
PMab-225_epitope PMab-44_alpaca |
done | |
RIEDL tag LpMab-7 | Character | Application | Ref | Gene cloning | Company |
anti-RIEDL tagmAb (LpMab-7; mouse IgG1, kappa)-->PAtag |
RIEDLtag (RIEDL; 5 amino acids): from AMED_SentanBio | Purification, IP, IHC, WB, FACS | RIEDL; PMab237 (1); PMab237 (2); C44-5; C44-46; E134; E51 | done | abcam |
MBP tag TMab-2 | Character | Application | Ref | Gene cloning | Company |
anti-MBP tag mAb (TMab-2; rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
done |
APRO |
anti-MBP tag mAb (YM-2;rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
done | BioLegend |
BAP tag PMab-44 | Character | Application | Ref | Gene cloning | Company |
anti-BAP tagmAb (PMab-44; mouse IgG1, kappa)--> PAtag |
BAP tag(EKTTLGVEDYTTTPAA; 16 amino acids); from AMED_BINDS_SentanBio | Purification, IP, IHC, WB, FACS | PMab247 PMab241 |
done |
APRO Zenogen |
LP tag LpMab-17 | Character | Application | Ref | Gene cloning | Company |
anti-LP tag mAb (LpMab-17; mouse IgG1, kappa)-->PAtag |
LPtag (NSVTGIRIEDLPTSES; 16 amino acids); from AMED_BINDS_SentanBio | Purification, IP, IHC, WB, FACS | PMab52 PMab231 |
done |
BD Merck |
His tag HisMab-1 | Character | Application | Ref | Gene cloning | Company |
anti-His tag (HisMab-1;mouse IgG2b, kappa)-->PAtag | His tag (HHHH; 4 amino acids); from AMED_SentanBio; Kd: 4.4 x 10^-9 M | Purification, IP, IHC, WB, FACS |
C20Mab60 Rituximab C20Mab11 |
done | |
anti-His tag (HisMab-1-hG1; human IgG1, kappa) | His tag (HHHH; 4 amino acids); from AMED_SentanBio | Purification, IP, IHC, WB, FACS | done | ||
anti-His tag (HisMab-1-scFv-mG2a; mouse IgG2a) | scFv of HisMab-1; Kd: 6.6 x 10^-9 M | IHC, WB, FACS | done |
antibody (mouse) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-62; mouse IgG1, kappa) | specific for SARS-CoV-2 S2 | ELISA isotype control of mouse IgG1 |
CvMab-62 | done | |
anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) | defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
anti-hamPDPN mAb (281-mG2a-f; mouse IgG2a, kappa) | defucocylated 281-mG2a | isotype control of mouse IgG2a in vivo |
H2Mab-214 H2Mab-77 |
done | |
anti-RdRP mAb (RdMab-20; mouse IgG2b, kappa) | specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP | ELISA, WB isotype control of mouse IgG2b |
RdMab-20 | done | |
anti-RdRP mAb (RdMab-13; mouse IgM, kappa) | specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP | ELISA, WB isotype control of mouse IgM |
RdMab-13 | done | |
antibody (rat) | Character | Application | Ref | Gene cloning | Company |
anti-mTERT mAb (TmMab-1; rat IgG1, kappa) | specific for mTERT | ELISA, WB isotype control of rat IgG1 |
done | ||
anti-mTERT mAb (TmMab-2; rat IgG2a, kappa) | specific for mTERT | ELISA isotype control of rat IgG2a |
done | ||
anti-IDH1 mAb(RcMab-1; rat IgG2a, kappa) | specific for IDH1 | IHC, WB isotype control of rat IgG2a |
RcMab-1 | done |
abcam CST MBL |
anti-IDH2-R172K mAb (KMab-1; rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB isotype control of rat IgG2b |
KMab-1 | done | abcam MBL |
antibody (human) | Character | Application | Ref | Gene cloning | Company |
anti-SARS-CoV-2 mAb (humCvMab-62; human IgG1, kappa) | specific for SARS-CoV-2 S2 | ELISA isotype control of human IgG1 |
done |
mouse CCR1 (CD191) | Character --> anti-human CCR1 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR1 mAb (C1Mab-1; rat IgG2b, lambda) | CBIS method; Kd: 1.5 x 10^-8 M ref: clone S15040E (BioLegend); rat IgG2b; Kd: 3.5 x 10^-8 M; no mAb from BD (summary) |
FACS, WB | done | ||
anti-mouse CCR1 mAb (C1Mab-2; rat IgG2b, lambda) | CBIS method Kd: 3.9 x 10^-9 M |
FACS, WB | done | ||
anti-mouse CCR1 mAb (C1Mab-5; rat IgG2b, lambda) | CBIS method Kd: 1.2 x 10^-8 M |
FACS, WB | done | ||
anti-mouse CCR1 mAb (C1Mab-6; rat IgG2b, kappa) | CBIS method Kd: 3.9 x 10^-9 M |
FACS, WB | C1Mab-6 | done |
mouse CCR2 (CD192) | Character --> anti-human CCR2 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR2 mAb (C2Mab-6; rat IgG1, kappa) |
ref: clone EPR20844-15 (abcam); rabbit IgG
ref: clone 475301 (BD); rat IgG2b ref: clone SA203G11 (BioLegend); rat IgG2b |
FACS, WB, ICC |
C2Mab-6 epitope (summary) |
done | BD |
mouse CCR3 (CD193) | Character --> anti-human CCR3 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR3 mAb(C3Mab-2; rat IgG2b, kappa) |
specific for mouse CCR3; established by CBIS method (summary) | FACS |
C3Mab-2 ICC |
done | |
anti-mouse CCR3 mAb (C3Mab-3; rat IgG2a, kappa0 | specifc mouse CCR3; established by CBIS method | FACS |
C3Mab-3 epitope |
done | |
anti-mouse CCR3 mAb (C3Mab-4; rat IgG2a, kappa) | specific mouse CCR3; established by CBIS method | FACS | epitope | done | |
anti-mouse CCR3 mAb (C3Mab-6; rat IgG1, kappa) | specific mouse CCR3; peptide immunization | FACS |
C3Mab-6 epitope |
done | |
anti-mouse CCR3 mAb (C3Mab-7; rat IgG1, kappa) | specific mouse CCR3; peptide immunization | FACS |
C3Mab-7 epitope-1 epitope-2 |
done |
mouse CCR4 (CD194) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR4 mAb (C4Mab-1; rat IgG1, kappa) | specific for mouse CCR4; peptide immunization
2G12 (BioLegend); hamster IgG no mAb from BD (summary) |
FACS |
C4Mab-1 epitope |
done | |
anti-mouse CCR4 mAb (C4Mab-1-mG2a-f; mIgG2a,k) | specific for mouse CCR4 | FACS | done |
mouse CCR5 (CD195) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR5 mAb (C5Mab-1; rat IgM, kappa) | specific for CCR5 (by CBIS method) ; ref: clone C34-3448 (BD); rat IgG2c; ref: clone HM-CCR5 (BioLegend); hamster (Kd: 1.6 x 10^-7) (summary) | FACS | done | ||
anti-mouse CCR5 mAb (C5Mab-2; rat IgG2b, kappa) | specific for CCR5 by CBIS method (Kd: 4.3 x 10^-8) |
FACS | C5Mab-2 | done | |
anti-mouse CCR5 mAb (C5Mab-3; rat IgG2b, kappa) | specific for CCR5 by CBIS method (Kd: 5.8 x 10^-8) |
FACS | done | ||
anti-mouse CCR5 mAb (C5Mab-4; rat IgG2a, kappa) | specific for CCR5 by peptide immunization (Kd: 3.5 x 10^-8) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | C5Mab-4 | done | |
anti-mouse CCR5 mAb (C5Mab-5; rat IgG2a, kappa) | specific for CCR5 by peptide immunization (Kd: 8.1 x 10^-8) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | done | ||
anti-mouse CCR5 mAb (C5Mab-7; rat IgG1, kappa) | specific for CCR5 by peptide immunization immunogen: MDFQGSVPTYSYDIDYGMS |
FACS | done | ||
anti-mouse CCR5 mAb (C5Mab-8; rat IgG1, kappa) | specific for CCR5 by peptide immunization (Kd: 7.3 x 10^-9) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | C5Mab-8 | done |
mouse CCR6 (CD196) | Character --> anti-human CCR6 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR6 mAb (C6Mab-9; rat IgG1, kappa) |
peptide immunization immunogen: MNSTESYFGTDDYDNTEYY (summary) |
FACS | done | ||
anti-mouse CCR6 mAb (C6Mab-9-mG2a-f; mIgG2a,k) | mouse IgG2a type of C6Mab-9 ref: clone 29-2L17 (BioLegend); hamster IgG ref: clone 140706 (BD); rat IgG2a |
FACS | done | ||
anti-mouse CCR6 mAb (C6Mab-10; rat IgG2a, kappa) | peptide immunization immunogen: MNSTESYFGTDDYDNTEYY |
FACS, WB | done | ||
anti-mouse CCR6 mAb (C6Mab-13; rat IgG1, kappa) | peptide immunization immunogen: MNSTESYFGTDDYDNTEYY |
FACS |
C6Mab-13 epitope |
done |
mouse CCR7 (CD197) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR7 mAb (C7Mab-2, rat IgG2b, kappa) | specific for mouse CCR7; ref: clone: 4B12 (Biolegend) | FACS | |||
anti-mouse CCR7 mAb (C7Mab-4, rat IgG2a, kappa) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-5, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-6, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-7, rat IgG1, kappa) | specific for mouse CCR7 | FACS, WB | in preparation (Satofuka et al) | ||
anti-mouse CCR7 mAb (C7Mab-8, rat IgG2a, lambda) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-9, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-10, rat Ig) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-11, rat IgG1, kappa) | specific for mouse CCR7 | FACS, WB(weak) | |||
anti-mouse CCR7 mAb (C7Mab-12, rat IgG2a, lambda) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-13, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-14, rat IgG1, kappa) | specific for mouse CCR7 | FACS | |||
anti-mouse CCR7 mAb (C7Mab-15, rat IgG1, kappa) | specific for mouse CCR7 | FACS, WB(weak) |
mouse CCR8 (CD198) | Character --> anti-human CCR8 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR8 mAb (C8Mab-1; rat IgG2a, kappa) |
clone SA214G2 (BioLegend); rat IgG2b no mAb from BD patent (Shionogi/Osaka Univ.) (summary) |
FACS, ICC | C8Mab-1 | done | |
anti-mouse CCR8 mAb (C8Mab-2; rat IgG2b, kappa) |
specific mouse CCR8 established by CBIS method |
FACS, ICC |
C8Mab-2 ICC epitope |
done | Merck |
anti-mouse CCR8 mAb (C8Mab-2-mG2a) | mouse IgG2a type of C8Mab-2 established by CBIS method |
FACS, ICC | done |
|
|
anti-mouse CCR8 mAb (C8Mab-3; rat IgG1, kappa) |
specific mouse CCR8 established by CBIS method |
FACS, ICC | C8Mab-3 | done |
mouse CCR9 (CD199) | Character --> anti-human CCR9 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR9 mAb (C9Mab-24; rat IgG2a, kappa) | immunogen: MMPTELTSLIPGMFDDFSYC (summary) ref: clone 9B1 (BioLegend; BD); rat IgG2a ref: clone CW-1.2 (BioLegend; BD); mouse IgG2a |
FACS, WB |
C9Mab-24 epitope |
done |
mouse CCR10 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR10 mAb (CC10Mab-1; rat IgM, kappa) | CBIS method
(summary) ref: clone 248918R (R&D); rat IgG2a |
FACS | in preparation (Li et al) |
mouse CXCR1 (CD181) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CXCR1 mAb (Cx1Mab-1; rat IgG1, kappa) | by CBIS; Kd: 2.6 x 10^-9 M (summary) ref: clone 1122A (R&D); rabbit IgG; Kd: 2.7 x 10^-9 M; clone U45-632 (BD); rat IgG2b |
FACS, WB | Cx1Mab-1 | done | |
anti-mouse CXCR1 mAb (Cx1Mab-2; rat IgG1, kappa) | Kd: 2.0 x 10^-9 M
immunogen: MAEAEYFIWTNPEGDFEKE |
FACS WB (weak) |
|||
anti-mouse CXCR1 mAb (Cx1Mab-3; rat IgG2a, kappa) | Kd: 6.2 x 10^-10 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS WB (weak) |
|||
anti-mouse CXCR1 mAb (Cx1Mab-4; rat IgG1, kappa) | Kd: 2.1 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | |||
anti-mouse CXCR1 mAb (Cx1Mab-5; rat IgG2a, kappa) | Kd: 8.2 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS, WB | |||
anti-mouse CXCR1 mAb (Cx1Mab-6; rat IgG1, kappa) | Kd: 1.0 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | |||
anti-mouse CXCR1 mAb (Cx1Mab-7; rat Ig2b, kappa) | Kd: 8.1 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | |||
anti-mouse CXCR1 mAb (Cx1Mab-8; rat Ig2b, kappa) | Kd: 3.0 x 10^-10 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | in preparation (Li G et al) |
mouse CXCR2 (CD182) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CXCR2 mAb (Cx2Mab-1; rat IgG2b, kappa) | immunogen: MGEFKVDKFNIEDFFSGDL; Kd: 9.4 x 10^-9 M; ref: SA045E1 (BioLegend; Kd: 1.6 x 10^-8 M) | FACS | in preparation (Kaneko et al) | done | |
anti-mouse CXCR2 mAb (Cx2Mab-2; rat IgG2b, kappa) | immunogen: MGEFKVDKFNIEDFFSGDL Kd: 1.0 x 10^-8 M (summary) |
FACS | done | ||
anti-mouse CXCR2 mAb (Cx2Mab-3; rat Ig) | specific for mouse CXCR2; by CBIS method | FACS | in preparation (Kobayashi et al) | ||
anti-mouse CXCR2 mAb (Cx2Mab-4; rat Ig) | specific for mouse CXCR2; by CBIS method | FACS |
mouse CXCR3 (CD183) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CXCR3 mAb (Cx3Mab-2; rat IgG2b, kappa) | immunogen: MYLEVSERQVLDASDFAFL (summary) Kd: 5.9 x 10^-9 M; ref: clone: CXCR3-173 (BD; BioLegend); hamster IgG; Kd: 1.3 x 10^-9 M |
FACS | done | ||
anti-mouse CXCR3 mAb (Cx3Mab-4; rat IgG1, kappa) | immunogen: MYLEVSERQVLDASDFAFL Kd: 1.3 x 10^-9 M |
FACS | Cx3Mab-4 | done | |
anti-mouse CXCR3 mAb (Cx3Mab-5; rat IgG2c, kappa) | immunogen: MYLEVSERQVLDASDFAFL Kd: 5.3 x 10^-9 M |
FACS | done | ||
anti-mouse CXCR3 mAb (Cx3Mab-6; rat IgG2b, kappa) | immunogen: MYLEVSERQVLDASDFAFL Kd: 4.5 x 10^-9 M |
FACS | done |
mouse CXCR4 (CD184) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CXCR4 mAb (Cx4Mab-1; rat IgG2a, kappa) | by CBIS method; Kd: 6.4 x 10^-9 M; ref: clone 2B11/CXCR4 (BD), rat IgG2b; ref: clone
L276F12 (BioLegend), rat IgG2b (summary)
|
FACS | Cx4Mab-1 | done | |
anti-mouse CXCR4 mAb (Cx4Mab-2; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG; Kd: 3.0 x 10^-7 M |
FACS, WB | in preparation (Yamamoto et al) | ||
anti-mouse CXCR4 mAb (Cx4Mab-3; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG |
FACS | |||
anti-mouse CXCR4 mAb (Cx4Mab-4; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG; Kd: 5.5 x 10^-7 M |
FACS, WB | |||
anti-mouse CXCR4 mAb (Cx4Mab-5; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG |
FACS |
mouse CXCR5 (CD185) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CXCR5 mAb (Cx5Mab-2; rat IgG2a, kappa) | immunogen: MNYPLTLDMGSITYNMDDL Kd: 7.0 x 10^-9; ref: clone 2G8 (BD) ; ref: clone L138D7 (BioLegend) (summary) |
FACS | |||
anti-mouse CXCR5 mAb (Cx5Mab-3; IgG2b, kappa) | specific for mouse CXCR5; immunogen: MNYPLTLDMGSITYNMDDL Kd: 7.2 x 10^-10 |
FACS | submit (Ishikawa et al) | ||
anti-mouse CXCR5 mAb (Cx5Mab-4; IgM, kappa) | specific for mouse CXCR5; immunogen: MNYPLTLDMGSITYNMDDL |
FACS |
mouse CXCR6 (CD186) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CXCR6 mAb(Cx6Mab-1; rat IgG1, kappa) | specific for mouse CXCR6; immunogen: MDDGHQESALYDGHYEGDF (summary) |
FACS, WB |
Cx6Mab-1 epitope-1 epitope-2 |
done | |
anti-mouse CXCR6 mAb(Cx6Mab-5; rat IgG1, kappa) | specific for mouse CXCR6; immunogen: MDDGHQESALYDGHYEGDF | FACS, WB | done |
mouse CX3CR1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CX3CR1 mAb (X3Mab-1; rat IgG1, kappa) | immunogen: MSTSFPELDLENFEYDDSA ref: clone SA011F11 (BioLgend): mouse IgG2a; ref: clone Z8-50 (BD): rat IgG2a |
FACS (weak), WB (weak) | |||
anti-mouse CX3CR1 mAb (X3Mab-2; rat IgG1, kappa) | specific for mouse CX3CR1 immunogen: MSTSFPELDLENFEYDDSA |
FACS (weak), WB (weak) |
mouse ACKR1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse ACKR1 mAb (A1Mab series) | specific for ACKR1 ref |
FACS |
mouse ACKR2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse ACKR2 mAb (A2Mab series) | specific for ACKR2 | FACS |
mouse ACKR3 (CD187, CXCR7) | Character (summary) | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse ACKR3 mAb (A3Mab-1; rat IgG2a, kappa) | specific for mouse ACKR3; immunogen: MDVHLFDYAEPGNYSDINW; ref: 8F11-M1 (BioLegend; Kd: 8.3 x 10^-8 M) | FACS | in preparation (Yamamoto et al) | done | |
anti-mouse ACKR3 mAb (A3Mab-2; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.5 x 10^-8 M | FACS, WB | |||
anti-mouse ACKR3 mAb (A3Mab-3; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 2.0 x 10^-8 M | FACS, WB | |||
anti-mouse ACKR3 mAb (A3Mab-4; rat IgG2a, kappa | specific for mouse ACKR3 | FACS | |||
anti-mouse ACKR3 mAb (A3Mab-5; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 2.6 x 10^-9 M | FACS | |||
anti-mouse ACKR3 mAb (A3Mab-6; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.9 x 10^-8 M | FACS, WB | |||
anti-mouse ACKR3 mAb (A3Mab-7; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.5 x 10^-8 M | FACS, WB | |||
anti-mouse ACKR3 mAb (A3Mab-8; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.9 x 10^-8 M | FACS |
mouse ACKR4 (CCR11, CCRL1) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse ACKR4 mAb (A4Mab-1; rat IgG2b, kappa) |
immunogen: MALELNQSAEYYYEENEMN; Kd: 3.5 x 10^-9 no commercially available mAb |
FACS, WB(weak) | A4Mab-1 | ||
anti-mouse ACKR4 mAb (A4Mab-2; rat IgG2b, kappa) |
immunogen: MALELNQSAEYYYEENEMN
Kd: 6.1 x 10^-9 |
FACS, WB | A4Mab-2 | ||
anti-mouse ACKR4 mAb (A4Mab-3; rat IgG2b, kappa) |
immunogen: MALELNQSAEYYYEENEMN
Kd: 1.6 x 10^-9 |
FACS | A4Mab-3 |
mouse ACKR5 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse ACKR5 mAb (A5Mab series) | also known as CCRL2 ref: clone S21013E (BioLegend) |
FACS |
mouse XCR1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mXCR1 mAb | in preparation | FACS |
human CCR1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR1 mAb |
in preparation |
human CCR2 (CD192) | Character --> anti-mouse CCR2 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR2 mAb (C2Mab-9; mouse IgG1, kappa) |
specific for human CCR2; expressed in U937 or NK cell; peptide immunization | FACS, ICC |
C2Mab-9 epitope |
done |
human CCR3 | Character --> anti-mouse CCR3 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR3 mAb (C3Mab-8; mouse IgG1, kappa)
|
specific for human CCR3 peptide immunization; Kd: 5.0 x 10^-9 M ref: 5E8 (BioLegend); Kd: 2.5 x 10^-9 M |
FACS, WB | done |
human CCR4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR4 mAb |
in preparation |
human CCR5 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR5 mAb |
in preparation |
human CCR6 (CD196) | Character --> anti-mouse CCR6 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR6 mAb (C6Mab-19; mouse IgG1, kappa) | specific for human CCR6; expressed in HepG2 or HuH-7; peptide immunization |
FACS, IHC, ELISA | C6Mab-19 |
human CCR7 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR7 mAb |
in preparation |
human CCR8 | Character --> anti-mouse CCR8 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR8 mAb (C8Mab-20; mouse IgG1, kappa) |
specific for human CCR8; peptide immunization; Kd: 3.2 x 10^-7 M; ref: S19017D, L263G8 (BioLegend); 433H (BD) | FACS | done | ||
anti-hCCR8 mAb (C8Mab-21; mouse IgM, kappa) | specific for human CCR8 CBIS method Kd: 6.5 x 10^-8 M |
FACS | C8Mab-21 | done |
human CCR9 (CD199) | Character --> anti-mouse CCR9 | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR9 mAb (C9Mab-1; mouse IgG1, kappa) | specific for human CCR9; developmed by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS |
C9Mab-1;
epitope ICC |
done | BD; exbio |
anti-hCCR9 mAb (C9Mab-6; mouse IgG1, kappa) | specific for human CCR9; established by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-8; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-9; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-10; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-11; mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS, WB |
C9Mab-11 epitope |
done | |
anti-hCCR9 mAb (C9Mab-12; mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-13; mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-14; mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-1016; mouse IgG1, kappa) |
specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-17; mouse IgG2b, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-18; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-1019; mouse IgG1, kappa) |
specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
anti-hCCR9 mAb (C9Mab-21; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done |
human CCR10 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR10 mAb |
in preparation |
human CCR11 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR11 mAb |
in preparation |
human CXCR1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR1 mAb |
in preparation |
human CXCR2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR2 mAb |
in preparation |
human CXCR3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR3 mAb |
in preparation |
human CXCR4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR4 mAb |
in preparation |
human CXCR5 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR5 mAb |
in preparation |
human CXCR6 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR6 mAb |
in preparation |
human CXCR7 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCXCR7 mAb |
in preparation |
human XCR1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hXCR1 mAb (X1Mab-4; mouse IgG1, kappa) | specific for human XCR1; established by peptide immunization | FACS | done | ||
anti-hXCR1 mAb (X1Mab-29; mouse IgM, kappa) | specific for human XCR1; established by peptide immunization | FACS | done | ||
anti-hXCR1 mAb (X1Mab-47; mouse IgM, kappa) | specific for human XCR1; established by CBIS (immunization of MDA-MB-157/PA-hXCR1) | FACS |
mouse EGFR domain-I | Character --> human EGFR | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb; EMab-300 (rat IgG1, kappa) | specific for mouse EGFR | FACS | EMab-300 | done | |
anti-EGFR mAb; EMab-305 (rat IgG1, lambda) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-306 (rat IgG1, lambda) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-307 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-308 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-309 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb (EMab-310; rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-311 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-312 (rat IgM, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-313 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
anti-EGFR mAb; EMab-314 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
mouse EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb; EMab-301 (rat IgM, kappa) | mouse EGFR was immunized using CBIS; cross-react with human EGFR | FACS, WB | done | ||
mouse EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb; EMab-301-rG2a (rat IgG2a, kappa) | rat IgG2a version of EMab-301; mouse EGFR was immunized using CBIS; cross-react with human EGFR | FACS, WB | done | ||
mouse EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
anti-mouse/human EGFR mAb; EMab-88 (mouse IgG1, kappa) | specific for EGFR; EMab-88 was developed against human EGFR; crossreacts with mouse EGFR (domain-III) | FACS | data | done | |
human EGFR domain-I | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-23; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-I | FACS | done | ||
anti-EGFR mAb (EMab-78; mouse IgG2b, kappa) |
specific for EGFR; reacts with domain-I | FACS | done | ||
anti-EGFR mAb (EMab-129; mouse IgG1, lambda) |
specific for EGFR; reacts with domain-I | FACS | done | ||
human EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-19; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | done | ||
anti-EGFR mAb (EMab-33; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | done | ||
anti-EGFR mAb (EMab-57; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | done | ||
anti-EGFR mAb (EMab-76; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | done | ||
human EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-134; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-134
epitope-1; -2 AirID |
done |
abcam BD |
anti-EGFR mAb (134-mG2a; mouse IgG2a, kappa) |
mouse IgG2a version of EMab-134; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC/CDC, antitumor activities | 134-mG2a | done | |
anti-EGFR mAb (EMab-51; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-51 epitope |
done | |
anti-EGFR mAb (51-mG2a; mouse IgG2a, kappa) |
mouse IgG2a version of EMab-51specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | done | ||
anti-EGFR mAb (51-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-51; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | done | ||
anti-EGFR mAb (EMab-17; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | EMab-17 metastasis |
done | |
anti-EGFR mAb (recEMab-17-f; mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-17; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | done | ||
anti-EGFR mAb (EMab-1; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
anti-EGFR mAb (EMab-32; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
anti-EGFR mAb (EMab-114; mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
anti-EGFR mAb (EMab-125; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | done | ||
anti-EGFR mAb (EMab-139; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | done | ||
anti-EGFR mAb (EMab-151; mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
anti-EGFR mAb (cetuximab; human IgG1,kappa) |
specific for EGFR (Erbitax) | FACS | done | ||
anti-EGFR mAb (panitumumab; human IgG2,kappa) |
specific for EGFR (Vectibix; epitope) | FACS | done | ||
human EGFR domain-IV | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-95; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | done | ||
anti-EGFR mAb (EMab-110; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | done | ||
dog EGFR | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (134-mG2a-f; mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR OS; Fibro Mammary |
done | |
anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
bispecific | Character | Application | Ref | Gene cloning | Company |
anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
anti-EGFR-PDPN mAb (E134-NZ1scFv-mG2a-f) |
bispecific mAb for EGFR and PDPN | FACS, WB, IHC, ADCC, CDC, antitumor activities | done |
mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-300 ; rat IgG2b, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS | H2Mab-300 | done | |
anti-HER2 mAb (H2Mab-303 ; rat IgG2a, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS | done | ||
anti-HER2 mAb (H2Mab-304 ; rat IgG1, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS, WB | H2Mab-304 | done | |
anti-HER2 mAb (H2Mab-307 ; rat IgG2a, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS | done | ||
anti-HER2 mAb (H2Mab-314 ; rat IgG1, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS, WB | done | ||
HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-77; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | H2Mab-77 | done | BioLegnd |
anti-HER2 mAb (H2Mab-77-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | 77-mG2a-f | done | |
anti-HER2 mAb (H2Mab-77-hG1; human IgG1) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | done | ||
anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done | |
anti-HER2 mAb (H2Mab-119; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-119 structure H2Mab-250 |
done | |
anti-HER2 mAb (H2Mab-119-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | 119-mG2a-f | done | |
anti-HER2 mAb (H2Mab-119-hG1; human IgG1) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | done | ||
anti-HER2 mAb (H2Mab-139; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-139 | done | abcam |
anti-HER2 mAb (H2Mab-139-mG2a;mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | done | ||
anti-HER2 mAb (H2Mab-139-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | 139-mG2a-f | done | |
anti-HER2 mAb (H2Mab-1245; mouse IgG1,kappa) |
Mab-34; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
anti-HER2 mAb (H2Mab-1268; mouse IgG1,kappa) |
Mab-35; specific for HER2 or endogenous dog HER2 | FACS | done | ||
anti-HER2 mAb (H2Mab-1278; mouse IgG1,kappa) |
Mab-38; specific for HER2 or endogenous dog HER2 | FACS | done | ||
HER2 domain-II | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-32; mouse IgG1, kappa) |
specific for HER2 | FACS |
|
done | |
anti-HER2 mAb (H2Mab-133; mouse IgG1, kappa) |
specific for HER2 | FACS |
|
done | |
anti-HER2 mAb (H2Mab-193; mouse IgG1, kappa) |
specific for HER2 | FACS | H2Mab-250 | done | |
anti-HER2 mAb (H2Mab-215; mouse IgG1, kappa) |
specific for HER2 | FACS | H2Mab-250 | done | |
(anti-HER2 mAb (pertuzumab; human IgG1,kappa) |
specific for HER2 (Perjeta) | FACS | done | ||
HER2 domain-III | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-19; mouse IgG2b, kappa) |
specific for HER2; crossreacts with mouse HER2 or dog HER2; domain-III | FACS, ADCC/CDC, antitumor activities | H2Mab-19 (PC)
CRC GBM |
done | |
anti-HER2 mAb (H2Mab-181; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; domain-III; epitope: p373-392 | FACS, WB, IHC | H2Mab-181 epitope |
done | |
anti-HER2 mAb (H2Mab-1180; mouse IgG1, kappa) |
Mab-33; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
anti-HER2 mAb (H2Mab-1190; mouse IgG1,kappa) |
Mab-36; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
anti-HER2 mAb (H2Mab-1262; mouse IgG1,kappa) |
Mab-37; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
HER2 domain-IV | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
(anti-HER2 mAb (trastuzumab; human IgG1,kappa) |
specific for HER2 | FACS | H2Mab-250 H2Mab-214 |
done | |
anti-HER2 mAb (trastuzumab-f; human IgG1,kappa) |
defucosylated trastuzumab; specific for HER2 | FACS |
250_in vivo |
done | |
anti-HER2 mAb (tras-mG2a-f; mouse IgG2a,kappa) |
specific for HER2 mouse IgG2a-version of trastuzumab defucosylated |
FACS | 250_in vivo | done |
HER3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti HER3 mAb (H3Mab-17; mouse IgG2a, kappa) |
specific for HER3 | FACS, ADCC/CDC, antitumor activities | H3Mab-17 | done | exbio |
anti-HER3 mAb (patritumab; human IgG2,kappa) |
specific for HER3 (Patritumab) | FACS | done |
HER4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER4 mAb (H4Mab-12; mouse IgG2a, kappa) | Kd: 3.1 x 10^-10 M for T-47D ref: clone P6-1 (BD; CosmoBio: rat IgG2a; Kd: 2.8 x 10^-10 M for T-47D) |
FACS | done | ||
anti-HER4 mAb (H4Mab-16; mouse IgG1, kappa) | immunization of LN229/HER4 Kd: 1.2 x 10^-9 M for T-47D |
FACS | done |
KLRG1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-KLRG1 mAb (KLMab-1; mouse IgG1, kappa) |
specific for human KLRG1 | FACS, ICC | KLMab-1 ICC |
done |
PD-L1 (CD274/B7H1) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L1 mAb (L1Mab-13; mouse IgG1, kappa) |
specific for human PD-L1 | FACS, WB, IHC (cell), IHC (tissue), ELISA | L1Mab-13 | done | |
anti-PD-L1 mAb (13-mG2a-f; mouse IgG2a, kappa) |
specific for human PD-L1; core fucose-deficient IgG2a of L1Mab-13 | FACS, WB, IHC (cell), IHC (tissue), ELISA, ADCC/CDC, antitumor activities | 13-mG2a-f | done | |
dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 (extracellular domain) | FACS, IHC | done | ||
anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done |
PD-L2 (CD273/B7H2) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L2 mAb (L2Mab-1; mouse IgG2b, kappa) |
specific for PD-L2 | FACS, WB, IHC (cell) | done |
TIGIT | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TIGIT mAb (TgMab-1; mouse IgG1, kappa) |
specific for TIGIT | FACS KD: 6.7 x 10^-10 |
done | ||
anti-TIGIT mAb (TgMab-2; mouse IgG1, kappa) |
specific for TIGIT | FACS, WB, ICC KD: 3.5 x 10^-9 |
TgMab-2 ICC |
done | BD |
CA4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CA4 mAb (CA4Mab-1; rat IgG1, kappa) |
specific for mouse carbonic anhydrase IV (CA4) | FACS, ELISA | done | ||
anti-CA4 mAb (CA4Mab-2; rat IgG1, kappa) |
specific for mouse carbonic anhydrase IV (CA4) | FACS, ELISA | done |
CD10 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD10 mAb (C10Mab-31; mouse IgG1, kappa) |
specific for CD10; CBIS method | FACS | C10Mab-31 RCC |
done |
CD19 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD19 mAb (C19Mab-1; mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | C19Mab-1 | done | |
anti-CD19 mAb (C19Mab-3; mouse IgG1, kappa) |
specific for CD19; CBIS method; ectodomain of CD19 immunization | IHC,WB | C19Mab-3 | done |
CD20 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD20 mAb (C20Mab-11; mouse IgM, kappa) |
specific for CD20 | FACS, WB, IHC |
C20Mab-11 epitope |
ongoing | |
anti-CD20 mAb (C20Mab-60; mouse IgG2a, kappa) |
specific for CD20; ref: rituximab | FACS, WB, IHC | C20Mab-60 epitope-1 epitope-2 |
done | BioLegnd |
CD20 | Character | Application | Ref | Gene cloning | Company |
anti-CD20 mAb (rituximab; human IgG1, kappa) |
specific for human CD20 (Rituxan) | FACS | done | ||
anti-CD20 mAb (obinutuzumab; human IgG1, kappa) |
specific for human CD20 (GAZYVA) | FACS | done | ||
anti-CD20 mAb (ofatumumab; human IgG1, kappa) |
specific for human CD20 (Kesimpta) | FACS | done |
CD39 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD39 mAb (C39Mab-1; rat IgG2a, kappa) |
specific for mouse CD39 | FACS, WB |
C39Mab-1
epitope |
done | |
anti-CD39 mAb (C39Mab-2; rat IgG2a, lambda) |
specific for mouse CD39 | FACS | C39Mab-2 | done | |
CD39 | Character | Application | Ref | Gene cloning | Company |
anti-CD39 mAb (C39Mab-1-ratM; rat IgM, kappa) |
specific for mouse CD39 | FACS, WB | done |
CD44s | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44s mAb (C44Mab-5; mouse IgG1, kappa) |
Specific for CD44s (CD44 standard) | IHC, FACS, WB | C44Mab-5 epitope 5-mG2a-f |
done | abcam BioLegnd |
anti-CD44s mAb (C44Mab-46; mouse IgG1, kappa) |
specific for CD44s (CD44 standard) | FACS, IHC, WB | C44Mab-46 epitope1 epitope2 C44Mab-46-mG2a |
done | |
CD44v3 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v3 mAb (C44Mab-6; mouse IgG1, kappa) |
specific for CD44v3 (oral cancer and colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-6(IJMS) FACS(CAS) |
done | |
CD44v4 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v4 mAb (C44Mab-108; mouse IgG1, kappa) |
specific for CD44v4 (oral cancer) |
WB, IHC, ELISA | C44Mab-108(CIMB) epitope(MAB) |
done | Merck |
CD44v5 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v5 mAb (C44Mab-3; mouse IgG1, kappa) |
specific for CD44v5 (pancreatic cancer) |
FACS, WB, IHC, ELISA | C44Mab-3 (antibodies) |
done | Merck |
CD44v6 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v6 mAb (C44Mab-9; mouse IgG1, kappa) |
specific for CD44v6 (colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-9 (IJMS) |
done | Merck |
CD44v7 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v7/v8 mAb (C44Mab-34; mouse IgG1, kappa) |
specific for CD44v7/v8 (oral cancer) |
FACS, WB, IHC, ELISA | C44Mab-34 (Biomedicines) |
done | |
CD44v8 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v8 mAb (C44Mab-94; mouse IgG1, kappa) |
specific for CD44v8 (gastric cancer) |
FACS, WB, IHC, ELISA | C44Mab-94 (antibodies) |
done | |
CD44v9 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v9 mAb (C44Mab-1; mouse IgG1, kappa) |
specific for CD44v9 (colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-1(CIMB) FACS(CAS) |
done | |
CD44v10 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v10 mAb (C44Mab-18; mouse IgM, kappa) |
specific for CD44v10 (oral cancer) |
FACS, WB, IHC, ELISA | C44Mab-18(CIMB) C44Mab-18-mG2a |
done | |
CD44s | Character | Application | Ref | Gene cloning | Company |
anti-CD44s mAb (5-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-5; specific for CD44s (CD44 standard) | IHC, FACS, ADCC, CDC, antitumor activities | 5-mG2a-f | done | |
anti-CD44s mAb (C44Mab-46-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-46 specific for CD44s (CD44 standard) |
IHC, FACS, WB | C44Mab-46-mG2a | done | |
CD44v3 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v3 mAb (C44Mab-6-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-6 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
CD44v4 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v4 mAb (C44Mab-112; mouse IgG1, kappa) |
specific for CD44v4 crossreact with mouse CD44 |
WB, IHC, ELISA | done | ||
anti-CD44v4 mAb (C44Mab-118; mouse IgG1, kappa) |
specific for CD44v4 crossreact with mouse CD44 |
WB, IHC, ELISA | done | ||
CD44v5 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v5 mAb (C44Mab-3-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-3 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
CD44v6 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v6 mAb (C44Mab-9-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-9 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v6 mAb (bivatuzumab; human IgG1, kappa) |
specific for CD44v6 | ref | done | ||
anti-CD44v6 mAb (biva-mG1; mouse IgG2a, kappa) |
specific for CD44v6 mouse IgG1 type |
||||
CD44v7 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v7/v8 mAb (C44Mab-34-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-34 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
CD44v8 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v8 mAb (C44Mab-94-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-94 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
CD44v9 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v9 mAb (C44Mab-1-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-1 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
CD44v10 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v10 mAb (C44Mab-18-mG1; mouse IgG1, kappa) |
mouse IgG1 version of CD44v10 | FACS, WB, IHC, ELISA | done | ||
anti-CD44v10 mAb (C44Mab-18-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-18 | FACS, WB, IHC, ELISA | C44Mab-18-mG2a | done |
CD73 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD73 mAb (C73Mab-1; rat IgG2a, lambda) | specific for mouse CD73 | FACS | in preparation (Kaneko et al) |
||
anti-CD73 mAb (C73Mab-2; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-3; rat IgM) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-4; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-5; rat Ig) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-6; rat IgG2a, kappa) | specific for mouse CD73 | FACS, WB | |||
anti-CD73 mAb (C73Mab-7; rat Ig) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-8; rat IgG2a, lambda) | specific for mouse CD73 | FACS, WB | |||
anti-CD73 mAb (C73Mab-9; rat IgG2a, lambda) | specific for mouse CD73 | FACS, WB | |||
anti-CD73 mAb (C73Mab-10; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-11; rat Ig) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-12; rat Ig) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-13; rat IgG2b, lambda) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-14; rat Ig) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-15; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
anti-CD73 mAb (C73Mab-16; rat IgG2a, lambda) | specific for mouse CD73 | FACS, WB | |||
anti-CD73 mAb (C73Mab-17; rat IgG2a, lambda) | specific for mouse CD73 | FACS |
CD133 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD133 mAb (CMab-43; mouse IgG2a, kappa) |
specific for CD133 | FACS, WB, IHC, ADCC/CDC, antitumor activities |
CMab-43 in vivo |
done |
abcam BD |
anti-CD133 mAb (CMab-44; mouse IgG1, kappa) |
specific for CD133; detects AML |
FACS, WB | done |
CD271 (NGFR) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD271 mAb (G4B1; mouse IgG2a, kappa) |
cancer-specific mAb for CD271 | FACS, WB, IHC | anti-CD271 mAb | done | Merck |
CD273 (PD-L2/B7H2) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L2 mAb | --> PD-L2 |
CD274 (PD-L1/B7H1) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L1 mAb | --> PD-L1 |
CD276 (B7H3) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD276 mAb (C276Mab-1; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-2; mouse IgG2b, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-3; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-4; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-5; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-6; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-7; mouse IgG3, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-8; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-9; mouse IgM, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-10; mouse IgM, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-11; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-12; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-13; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-14; mouse IgG2b, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-15; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-16; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-17; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-18; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-19; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-20; mouse IgG2a, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-21; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-22; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-23; mouse IgG2b, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-24; mouse IgG2b, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-25; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-26; mouse IgG1, kappa) | specific for CD276 | FACS, WB | |||
anti-CD276 mAb (C276Mab-27; mouse IgG1, kappa) | specific for CD276 | ||||
anti-CD276 mAb (C276Mab-28; mouse IgG1, kappa) | specific for CD276 |
CDH1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH1 mAb Ca1Mab series |
specific for CDH1 |
CDH2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH2 mAb Ca2Mab series |
specific for CDH2 |
CDH3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH3 mAb Ca3Mab-5 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-6 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-7 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-8 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-12 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-16 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-17 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-18 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-19 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
anti-CDH3 mAb Ca3Mab-20 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB |
CDH4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH4 mAb Ca4Mab series |
specific for CDH4 |
CDH5 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH5 mAb Ca5Mab series |
specific for CDH5 |
CDH6 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH6 mAb Ca6Mab series |
specific for CDH6 |
CDH7 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH7 mAb Ca7Mab series |
specific for CDH7 |
CDH8 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH8 mAb Ca8Mab series |
specific for CDH8 |
CDH9 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH9 mAb Ca9Mab series |
specific for CDH9 |
CDH10 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH10 mAb Ca10Mab series |
specific for CDH10 |
CDH11 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH11 mAb Ca11Mab series |
specific for CDH11 |
CDH12 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH12 mAb Ca12Mab series |
specific for CDH12 |
CDH13 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH13 mAb Ca13Mab series |
specific for CDH13 |
CDH15 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH15 mAb Ca15Mab series |
specific for CDH15 |
CDH16 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH16 mAb Ca16Mab series |
specific for CDH16 |
CDH17 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH17 mAb Ca17Mab series |
specific for CDH17 |
CDH18 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH18 mAb Ca18Mab series |
specific for CDH18 |
CDH19 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH19 mAb Ca19Mab series |
specific for CDH19 |
CDH20 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH20 mAb Ca20Mab series |
specific for CDH20 |
CDH21 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH21 mAb Ca21Mab series |
specific for CDH21 |
CDH22 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH22 mAb Ca22Mab series |
specific for CDH22 |
CDH23 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH23 mAb Ca23Mab series |
specific for CDH23 |
CDH24 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH24 mAb Ca24Mab series |
specific for CDH24 |
CDH25 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CDH25 mAb Ca25Mab series |
specific for CDH25 |
mouse EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EpCAM mAb (EpMab-160; rat IgG2b, kappa) |
specific for mouse EpCAM | FACS | in preparation (Li G et al) | ||
anti-EpCAM mAb (EpMab-161; rat IgG2b, kappa) |
specific for mouse EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-162; rat IgG2a, kappa) |
specific for mouse EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-163; rat IgG2c, kappa) |
specific for mouse EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-164; rat IgM, kappa) |
specific for mouse EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-165; rat IgG2a, kappa) |
specific for mouse EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-166; rat IgM, kappa) |
specific for mouse EpCAM crossreact with human EpCAM (only exogenous) |
FACS | |||
anti-EpCAM mAb (EpMab-167; rat IgM, kappa) |
specific for mouse EpCAM | FACS | |||
human EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
anti-EpCAM mAb (EpMab-16; mouse IgG2a, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-16 (1)
EpMab-16 (2) |
done | merck |
anti-EpCAM mAb (EpMab-37; mouse IgG1, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-37 epitope |
done | |
anti-EpCAM mAb (EpMab-37-mG2a-f; mouse IgG2a) |
specific for EpCAM | FACS, WB, IHC, ADCC, CDC, antitumor activities |
EpMab-37 (1) EpMab-37 (2) |
done | |
anti-EpCAM mAb (EpMab-3; mouse IgG1, kappa) |
specific for EpCAM | FACS | done |
EphA1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA1 mAb Ea1Mab-5 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-7 (mouse IgG2a, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-14 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-15 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-20 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-28 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-30 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-35 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-43 (mouse IgG2a, kappa) |
specific for EphA1 | FACS, WB | |||
anti-EphA1 mAb Ea1Mab-46 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB |
EphA2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA2 mAb Ea2Mab-1 (mouse IgG1, kappa) |
specific for EphA2 ref: clone SHM16 (BioLegend; Kd: 8.4 x 10^-9 for CHO/hEphA2) |
FACS | |||
anti-EphA2 mAb Ea2Mab-2 (mouse IgG2a, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-3 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-4 (mouse IgG2b, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-5 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-6 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-7 (mouse IgG1, kappa) |
specific for EphA2 Kd: 7.7 x 10^-9 for CHO/hEphA2 |
FACS, WB, IHC | Satofuka et al | done | |
anti-EphA2 mAb Ea2Mab-8 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-9 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-10 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-11 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
anti-EphA2 mAb Ea2Mab-12 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
EphA2 | Character | Application | Ref | Gene cloning | Company |
anti-EphA2 mAb Ea2Mab-7-mG2a (mouse IgG2a, kappa) |
mouse IgG2a version of Ea2Mab-7 | FACS, WB, IHC | |||
anti-EphA2 mAb Ea2Mab-7-hG1 (human IgG1, kappa) |
human IgG1 version of Ea2Mab-7 | FACS, WB, IHC |
EphA3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA3 mAb Ea3Mab-1 (mouse IgG1, kappa) |
specific for EphA3; Kd: 4.9 x 10^-9; ref: clone: IIIA4 (absolute antibody; Kd: 1.4 x 10^-9) | FACS | in preparation (Hirose et al) |
||
anti-EphA3 mAb Ea3Mab-2 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-3 (mouse IgG1, kappa) |
specific for EphA3; Kd: 8.8 x 10^-9 | FACS | |||
anti-EphA3 mAb Ea3Mab-4 (mouse IgG1, kappa) |
specific for EphA3; Kd: 2.3 x 10^-9 | FACS | |||
anti-EphA3 mAb Ea3Mab-5 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-6 (mouse IgM, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-7 (mouse IgG1, kappa) |
specific for EphA3; Kd: 6.7 x 10^-9 | FACS | |||
anti-EphA3 mAb Ea3Mab-8 (mouse IgG1, kappa) |
specific for EphA3; Kd: 4.6 x 10^-9 | FACS | |||
anti-EphA3 mAb Ea3Mab-9 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-10 (mouse IgG1, kappa) |
specific for EphA3; Kd: 2.5 x 10^-9 | FACS | |||
anti-EphA3 mAb Ea3Mab-11 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-12 (mouse IgG1, kappa) |
specific for EphA3; Kd: 4.6 x 10^-9 | FACS | |||
anti-EphA3 mAb Ea3Mab-13 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-14 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-15 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-16 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-17 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-18 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-19 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
anti-EphA3 mAb Ea3Mab-20 (mouse IgG1, kappa) |
specific for EphA3 | FACS |
EphA4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA4 mAb Ea4Mab-1 (mouse IgG1, kappa) |
specific for EphA4 | FACS | in preparation (Li et al) |
||
anti-EphA4 mAb Ea4Mab-2 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-3 (mouse IgG1, kappa) |
specific for EphA4 | FACS, WB | |||
anti-EphA4 mAb Ea4Mab-4 (mouse IgG2b, kappa) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-5 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-6 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-7 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-8 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-9 (mouse IgG) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-10 (mouse IgG) |
specific for EphA4 | FACS | |||
anti-EphA4 mAb Ea4Mab-11 (mouse IgG) |
specific for EphA4 | FACS |
EphA5 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA5 mAb Ea5Mab-1 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | in preparation (Li et al) |
||
anti-EphA5 mAb Ea5Mab-2 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
anti-EphA5 mAb Ea5Mab-3 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
anti-EphA5 mAb Ea5Mab-4 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
anti-EphA5 mAb Ea5Mab-5 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS, WB | |||
anti-EphA5 mAb Ea5Mab-6 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
anti-EphA5 mAb Ea5Mab-7 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS, WB |
EphA6 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA6 mAb (Ea6Mab-1, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | in preparation (Li G et al) |
||
anti-EphA6 mAb (Ea6Mab-2, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-3, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-4, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-5, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-6, mouse IgM, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-7, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-8, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | |||
anti-EphA6 mAb (Ea6Mab-9, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS |
EphA7 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA7 mAb Ea7Mab-1 (mouse IgM, kappa) |
specific for human EphA7 | FACS | in preparation (Yamamoto et al) |
||
anti-EphA7 mAb Ea7Mab-2 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 2.0 x 10^-9 M for CHO/EphA7 9.2 x 10^-9 M for LN229/EphA7 |
FACS, WB | |||
anti-EphA7 mAb Ea7Mab-3 (mouse IgG1, kappa) |
specific for human EphA7 | FACS | |||
anti-EphA7 mAb Ea7Mab-4 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 1.7 x 10^-8 M for CHO/EphA7 2.7 x 10^-8 M for LN229/EphA7 |
FACS, WB | |||
anti-EphA7 mAb Ea7Mab-5 (mouse IgG1, kappa) |
specific for human EphA7 | FACS, WB | |||
anti-EphA7 mAb Ea7Mab-6 (mouse IgG1, kappa) |
specific for human EphA7 | FACS | |||
anti-EphA7 mAb Ea7Mab-7 (mouse IgG1, kappa) |
specific for human EphA7 | FACS | |||
anti-EphA7 mAb Ea7Mab-8 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 8.7 x 10^-9 M for CHO/EphA7 4.7 x 10^-8 M for LN229/EphA7 |
FACS, WB | |||
anti-EphA7 mAb Ea7Mab-9 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 6.5 x 10^-7 M for CHO/EphA7 6.7 x 10^-5 M for LN229/EphA7 |
FACS, WB | |||
anti-EphA7 mAb Ea7Mab-10 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 1.3 x 10^-7 M for CHO/EphA7 6.5 x 10^-8 M for LN229/EphA7 |
FACS, WB | |||
anti-EphA7 mAb Ea7Mab-11 (mouse IgM, kappa) |
specific for human EphA7 | FACS | |||
anti-EphA7 mAb Ea7Mab-12 (mouse IgM, kappa) |
specific for human EphA7 | FACS | |||
anti-EphA7 mAb Ea7Mab-13 (mouse IgG1, kappa) |
specific for human EphA7 | FACS, WB |
EphA8 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA8 mAb (Ea8Mab-1, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 1.9 x 10^-9 for CHO/EphA8; no ref mAb |
FACS | in preparation (Yamamoto et al) | ||
anti-EphA8 mAb (Ea8Mab-2, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 2.3 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-3, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 3.4 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-4, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 8.7 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-5, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 2.2 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-6,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 5.5 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-7,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-8,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 4.1 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-9,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 1.3 x 10^-9 for CHO/EphA8 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-10,mouse IgG1, lambda) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-11,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 2.0 x 10^-9 |
FACS | |||
anti-EphA8 mAb (Ea8Mab-12,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-13,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-14,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-15,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-16,mouse IgG3, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-17,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
anti-EphA8 mAb (Ea8Mab-18,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS |
EphA10 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphA10 mAb Ea10Mab-1 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS | in preparation (Ubukata et al) |
||
anti-EphA10 mAb Ea10Mab-2 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS | |||
anti-EphA10 mAb Ea10Mab-3 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS | |||
anti-EphA10 mAb Ea10Mab-4 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS |
EphB1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphB1 mAb Eb1Mab-1 (mouse IgG1, kappa) |
specific for human EphB1 Kd: 4.1 x 10^-9 M |
FACS | in preparation (Yamamoto et al) |
done | |
anti-EphB1 mAb Eb1Mab-2 (mouse IgM, kappa) |
specific for human EphB1 | FACS | |||
anti-EphB1 mAb Eb1Mab-3 (mouse IgG1, kappa) |
specific for human EphB1 Kd: 2.5 x 10^-9 M |
FACS |
EphB2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphB2 mAb Eb2Mab-1 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 5.9 x 10^-9 for CHO/hEphB2; ref: clone 2H9 (BD; 3.4 x 10^-9 for CHO/hEphB2; Kd: 1.9 x 10^-9 for LS174T) | FACS | |||
anti-EphB2 mAb Eb2Mab-2 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 6.4 x 10^-9 for CHO/hEphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-3 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 1.1 x 10^-9 for CHO/hEphB2; 3.6 x 10^-10 for LS174T | FACS | Eb2Mab-3 | done | |
anti-EphB2 mAb Eb2Mab-4 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 3.3 x 10^-9 for CHO/hEphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-5 (mouse IgG3, kappa) |
specific for human EphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-6 (mouse IgM, kappa) |
specific for human EphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-7 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 5.2 x 10^-9 for CHO/hEphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-8 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 9.5 x 10^-9 for CHO/hEphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-9 (mouse IgM, kappa) |
specific for human EphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-10 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 3.4 x 10^-9 for CHO/hEphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-11 (mouse IgM, kappa) |
specific for human EphB2 | FACS | |||
anti-EphB2 mAb Eb2Mab-12 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 1.7 x 10^-9 for CHO/hEphB2; 4.4 x 10^-10 for LS174T | FACS | |||
EphB2 | Character | Application | Ref | Gene cloning | Company |
anti-EphB2 mAb Eb2Mab-3-mG2a-f (mouse IgG2a, kappa) |
mouse IgG2a version of Eb2Mab-3 | FACS | done |
EphB3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphB3 mAb Eb3Mab-1 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method; ref: clone 647354 (R&D) |
FACS | in preparation (Li et al) |
||
anti-EphB3 mAb Eb3Mab-2 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-3 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-4 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-5 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS, WB | |||
anti-EphB3 mAb Eb3Mab-6 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-7 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-9 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-10 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
anti-EphB3 mAb Eb3Mab-11 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS |
EphB4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphB4 mAb (Eb4Mab-1, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method ref: clone ab279601 (abcam) |
FACS, WB | |||
anti-EphB4 mAb (Eb4Mab-2, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS | |||
anti-EphB4 mAb (Eb4Mab-3, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
anti-EphB4 mAb (Eb4Mab-4, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
anti-EphB4 mAb (Eb4Mab-5, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
anti-EphB4 mAb (B4Mab-7, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB, IHC | B4Mab-7 | done | |
anti-EphB4 mAb (Eb4Mab-8, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
anti-EphB4 mAb (Eb4Mab-9, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB, IHC | |||
anti-EphB4 mAb (Eb4Mab-10, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS | |||
EphB4 | Character | Application | Ref | Gene cloning | Company |
anti-EphB4 mAb (Eb4Mab-7-mG2a-f, mouse IgG2a, kappa) | mouse IgG2a version of B4Mab-7 | FACS, WB, IHC | done |
EphB6 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EphB6 mAb Eb6Mab-1 (mouse IgG1,kappa) |
specific for human EphB6; established by CBIS method; ref: clone T49-25 (BioLegend; Kd: 1.3 x 10^-8 M for DLD-1; 1.5 x 10^-8 M for CHO/EphB6) | FACS | |||
anti-EphB6 mAb Eb6Mab-2 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method Kd: 8.7 x 10^-9 M for CHO/hEphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-3 (mouse IgG1, kappa) |
specific for human EphB6; established by CBIS method ; >Kd: 2.0 x 10^-9 M for DLD-1; 3.8 x 10^-8 M for CHO/EphB6 | FACS, WB | in preparation (Kaneko et al) | done | |
anti-EphB6 mAb Eb6Mab-4 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method< 3.6 x 10^-9 M for CHO/EphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-5 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-6 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 3.7 x 10^-9 M for CHO/EphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-7 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 3.0 x 10^-9 M for CHO/EphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-8 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 2.5 x 10^-9 M for CHO/EphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-9 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-10 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-11 (mouse IgM, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-12 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-13 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-14 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-15 (mouse IgG1, lambda) |
specific for human EphB6 established by CBIS method 8.4 x 10^-9 M for CHO/EphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-16 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-17 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-18 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-19 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-20 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS, WB (weak) | |||
anti-EphB6 mAb Eb6Mab-21 (mouse IgG2b, kappa) |
specific for human EphB6 established by CBIS method 7.5 x 10^-8 M for CHO/EphB6 |
FACS, WB (weak) | |||
anti-EphB6 mAb Eb6Mab-22 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-23 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method Kd: 3.0 x 10^-8 M for CHO/hEphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-24 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method Kd: 3.8 x 10^-8 M for CHO/hEphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-25 (mouse IgG1 or G2b, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-26 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-29 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-30 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 5.8 x 10^-9 M for CHO/EphB6 |
FACS | |||
anti-EphB6 mAb Eb6Mab-31 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-32 (mouse IgG1 (G2b), kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
anti-EphB6 mAb Eb6Mab-33 (mouse IgG1 (G2b), kappa) |
specific for human EphB6 established by CBIS method |
FACS |
GM3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GM3 mAb (DH2-mG1, mouse IgG1, kappa) | specific for human GM3 | FACS | DH2 | done |
GPC1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC1 mAb (G1Mab-1, mouse IgG2a, kappa) | specific for human GPC1 Kd: 4.5 x 10^-8 p.c.: 1019718 (R&D; Kd: 6.3 x 10^-8) |
FACS, WB | Yamamoto et al | ||
anti-GPC1 mAb (G1Mab-2, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-3, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-4, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-5, mouse IgG2b, kappa) | specific for human GPC1 Kd: 3.5 x 10^-8 |
FACS | |||
anti-GPC1 mAb (G1Mab-6, mouse IgG2b, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-7, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-8, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-9, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-10, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-11, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-12, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-13, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-14, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-15, mouse IgG1) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-16, mouse IgG2a, kappa) | specific for human GPC1 Kd: 1.4 x 10^-7 |
FACS, WB | |||
anti-GPC1 mAb (G1Mab-17, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-18, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-19, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-20, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-21, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-22, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-23, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-24, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-25, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-26, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-27, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-28, mouse IgG1, kappa) | specific for human GPC1 Kd: 3.3 x 10^-8 |
FACS, WB | |||
anti-GPC1 mAb (G1Mab-29, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-30, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-31, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-32, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-33, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-34, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-35, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-36, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-37, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-38, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
anti-GPC1 mAb (G1Mab-39, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-40, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
anti-GPC1 mAb (G1Mab-41, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB |
GPC2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC2 mAb (G2Mab-1, mouse IgG2a, kappa) | specific for human GPC2 | FACS | in preparation (Ishikawa et al) |
||
anti-GPC2 mAb (G2Mab-2, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-3, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-4, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-5, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-6, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-7, mouse IgG1, kappa) | specific for human GPC2 | FACS, WB | |||
anti-GPC2 mAb (G2Mab-8, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-9, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-10, mouse IgG2b, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-11, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-12, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-13, mouse IgG2a, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-14, mouse IgG2a, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-16, mouse IgG2a, kappa) | specific for human GPC2 | FACS | |||
anti-GPC2 mAb (G2Mab-17, mouse IgG1, kappa) | specific for human GPC2 | FACS |
GPC3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC3 mAb (G3Mab-4; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | in preparation | done | |
anti-GPC3 mAb (G3Mab-7; mouse IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
anti-GPC3 mAb (G3Mab-8; mouse IgG2a, kappa) |
specific for human GPC3 | FACS | done | ||
GPC3 | Character | Application | Ref | Gene cloning | Company |
anti-GPC3 mAb (G3Mab-4-mG1; mouse IgG1, kappa) |
specific for human GPC3 | FACS, WB | done | ||
anti-GPC3 mAb (G3Mab-4-mG2a; mouse IgG2a, kappa) |
specific for human GPC3 | FACS, WB | done | ||
anti-GPC3 mAb (humG3Mab-4; human IgG1, kappa) |
specific for human GPC3 | FACS, WB | done | ||
anti-GPC3 mAb (humG3Mab-7; human IgG1, kappa) |
specific for human GPC3 | FACS | done |
GPC4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC4 mAb (G4Mab-1, mouse IgM, kappa) | specific for human GPC4 | FACS | in preparatin (Li et al) |
||
anti-GPC4 mAb (G4Mab-2, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
anti-GPC4 mAb (G4Mab-3, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
anti-GPC4 mAb (G4Mab-4, mouse IgM, kappa) | specific for human GPC4 | FACS | |||
anti-GPC4 mAb (G4Mab-5, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
anti-GPC4 mAb (G4Mab-6, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
anti-GPC4 mAb (G4Mab-7, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
anti-GPC4 mAb (G4Mab-8, mouse IgG1, kappa) | specific for human GPC4 | FACS |
GPC5 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC5 mAb (G5Mab-1, mouse IgG1, kappa) | specific for human GPC5 | FACS | in preparatin (Kaneko et al) |
||
anti-GPC5 mAb (G5Mab-2, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-3, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-4, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-5, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-6, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-7, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-8, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-9, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-10, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-11, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-12, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-13, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-14, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-15, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-16, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-17, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
anti-GPC5 mAb (G5Mab-18, mouse IgG1, kappa) | specific for human GPC5 | FACS |
GPC6 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC6 mAb (G6Mab-1, mouse IgG1, kappa) | specific for human GPC6 | FACS | in preparatin (Yamamoto et al) |
||
anti-GPC6 mAb (G6Mab-2, mouse IgG2a, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-3, mouse IgM, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-4, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-5, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-6, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-7, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-8, mouse IgG3, kappa) | specific for human GPC6 | FACS | |||
anti-GPC6 mAb (G6Mab-9, mouse IgG1, kappa) | specific for human GPC6 | FACS |
TROP2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TROP2 mAb (TrMab-6; mouse IgG2b, kappa) |
specific for human TROP2; (ref: TNBC) | IHC, WB, FACS |
TrMab-6 MCF7 TNBC |
done |
exbio |
anti-TROP2 mAb (TrMab-29; mouse IgG1, kappa) |
specific for human TROP2 | IHC, WB, FACS | TrMab-29 | done | merck |
anti-TROP2 mAb (Datopotamab; humanized IgG1, kappa) |
Humanized mAb for DS-1062/Dato-DXd (Daiichi-Sankyo) | FACS | done | ||
anti-TROP2 mAb (Sacituzumab; humanized IgG1, kappa) |
Humanized mAb (Sacituzumab govitecan; Trodelvy) | FACS | done |
HGF | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HGF mAb (t8E4; mouse IgG1, kappa) |
specific for active HGF | WB, IHC |
SREP IJMS |
done | Merck |
anti-HGF mAb (t5A11; mouse IgG1, kappa) |
specific for HGF | WB, IHC |
SREP IJMS |
done | |
anti-HGF mAb (t1E4; mouse IgG2b, kappa) |
specific for HGF | neutralization |
SREP |
done |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PODXL mAb (PcMab-47; mouse IgG1, kappa) |
specific for human PODXL | FACS, WB, IHC | PcMab-47 IHC_OSCC epitope |
done | APRO abcam exbio |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
anti-PODXL mAb (47-mG2a; mouse IgG2a, kappa) |
IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a IHC_LK IHC_EC |
done | |
anti-PODXL mAb (47-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a-f | done | |
anti-PODXL mAb (chPcMab-47; human IgG1) |
specific for human PODXL | FACS, WB, IHC | chPcMab-47 | done |
human podoplanin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hPDPN mAb (NZ-1; rat IgG2a, lambda) |
specific for human PDPN | IP, IHC, WB, FACS (Review; patent) |
NZ-1 | done |
APRO |
anti-hPDPN mAb (NZ-1.2; rat IgG2a) |
specific for human PDPN; the other clones: NZ-1.3(Thermo), NC-08 (BioLegend) | IP, IHC, WB, FACS | NZ-1.2 |
done | Merck,MBL,Novus, Zenogen,Wako |
anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
done | |
anti-hPDPN mAb (LpMab-3; mouse IgG1, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS | LpMab-3 epitope Structure |
done | MCP |
anti-hPDPN mAb (LpMab-7 ;mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | LpMab-7 OS epitope |
done |
abcam MCP zenogen |
anti-hPDPN mAb (LpMab-9; mouse IgG1, kappa) | specific for human PDPN; epitope: Thr25 | WB, FACS | LpMab-9 epitope |
done | MCP |
anti-hPDPN mAb (LpMab-10; mouse IgG3, kappa) | specific for human PDPN; epitope: PLAG1 Thr34 | IHC, WB, FACS | LpMab-10 | done | |
anti-hPDPN mAb (LpMab-12; mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG3 Thr52 | IHC, WB, FACS | LpMab-12 | done |
APRO;
CST
Merck Hycult MCP, zenogen |
anti-hPDPN mAb (LpMab-13; mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG2-3 | IHC, WB, FACS | LpMab-13 | done | Merck Hycult |
anti-hPDPN mAb (LpMab-16; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | patent 2018-123699 | done | |
anti-hPDPN mAb (LpMab-17; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS press release |
LpMab-17 | done |
BD Merck Hycult |
anti-hPDPN mAb (LpMab-19; mouse IgG2b, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC | LpMab-19 | done | Merck |
anti-hPDPN mAb (LpMab-21; mouse IgG2a, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC press release |
Cells2022 LpMab-21 in vivo |
done |
Merck
BioLegend MCP |
anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab |
IHC, WB, FACS | LpMab-23 IHC patent |
done |
BD exbio |
human podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-human PDPN mAb (NZ-8; human IgG1, kappa) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-8 | done | |
anti-human PDPN mAb (NZ-12; human IgG1, lambda) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-12 RIT |
done | |
anti-human PDPN mAb (NZ-16; human IgG1, lambda) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | RIT | done | |
anti-human PDPN mAb (NZ-27; human IgG1, lambda) |
specific for human PDPN; humanized mAb originated from NZ-1 | IP, IHC, WB, FACS |
NZ-27 CAR-T |
done | |
anti-human PDPN mAb (chLpMab-7; human IgG1) | specific for human PDPN; mouse-human chimeric mAb originated from LpMab-7 | IHC, WB, FACS | chLpMab-7 | done |
mouse podoplanin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti mouse PDPN mAb (PMab-1; rat IgG2a, kappa) |
specific for mouse PDPN --> anti-human PDPN |
IHC, WB, FACS | PMab-1 PMab-1_LEC epitope |
done | abcam; MBL; Nov; Mer; BioL; BD |
anti-mouse PDPN mAb (mPMab-1; mouse IgG2a,kappa) | specific for mouse PDPN | IHC, WB, FACS |
mPMab-1 |
done | |
anti-mouse PDPN mAb (PMab-1-mG2a-f; mouse IgG2a,kappa) | specific for mouse PDPN | IHC, WB, FACS | done | ||
rat podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-rat PDPN mAb (PMab-2; mouse IgG1, kappa) |
specific for rat PDPN | IHC, WB, FACS | PMab-2 PMab-2_epitope |
done |
abcam Merck BioLegend |
rabbit podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-rabbit PDPN mAb (PMab-32; mouse IgG1, kappa) |
specific for rabbit PDPN | IHC, WB, FACS | PMab-32 epitope |
||
dog podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
bovine podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-bovPDPN mAb (PMab-44; mouse IgG1, kappa) | specific for bovine PDPN | IHC, WB, FACS | PMab-44;
epitope goat; sheep; alpaca |
done | zenogen |
cat podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-cat PDPN mAb (PMab-52; mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
done | zenogen |
tiger podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-tiger PDPN mAb (PMab-231; mouse IgG2a, kappa) |
specific for tiger PDPN | IHC, WB, FACS | PMab-231 epitope; lion |
done | zenogen |
tiger podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) |
defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
horse podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-horse PDPN mAb (PMab-219; mouse IgG2a, kappa) |
specific for horse PDPN | WB, FACS, IHC | PMab-219 epitope |
done | zenogen |
anti-horse PDPN mAb (PMab-202; mouse IgG1, kappa) |
specific for horse PDPN | WB, FACS | PMab-202 epitope |
done | zenogen |
pig podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-pig PDPN mAb (PMab-213; mouse IgG2b, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-213 epitope LEC |
done | zenogen |
anti-pig PDPN mAb (PMab-210; mouse IgG1, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-210 epitope |
done | zenogen |
goat podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-goat PDPN mAb (PMab-235; mouse IgG1, kappa) | specific for goat PDPN | IHC, WB, FACS | PMab-235 epitope |
done | zenogen |
alpaca podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-aPDPN mAb (PMab-225; mouse IgG2b, kappa) | specific for alpaca PDPN | IHC, WB, FACS |
PMab-225 epitope |
done | zenogen |
Tas_devil podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-TasPDPN PDPN (PMab-233; mouse IgG1, kappa) | specific for Tasmanian devil PDPN | IHC, WB, FACS | PMab-233 epitope |
done | zenogen |
bear podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-bear PDPN mAb (PMab-241; mouse IgG2b, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-241 epitope |
||
anti-bear PDPN mAb (PMab-247; mouse IgG1, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-247 IHC epitope |
done | zenogen |
whale podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-whale PDPN mAb (PMab-237; mouse IgG1, kappa) |
specific for whale PDPN | IHC, WB, FACS | PMab-237 IHC epitope |
done | zenogen |
sheep podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-sheep PDPN mAb (PMab-256; mouse IgG1, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-256 epitope |
done | zenogen |
anti-sheep PDPN mAb (PMab-253; mouse IgM, kappa) |
specific for sheept PDPN | IHC, WB, FACS | PMab-253 | done | |
anti-sheep PDPN mAb (PMab-260; mouse IgM, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-260 | done | |
sea lion podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-seaPDPN mAb (PMab-269; mouse IgG1, kappa) | specific for sea lion PDPN | IHC, WB, FACS | PMab-269 epitope Steller Sea Lion |
done | |
elephant podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-elePDPN mAb (PMab-265; mouse IgM, kappa) | specific for elephant PDPN | FACS | PMab-265 | ||
anti-elePDPN mAb (PMab-295; mouse IgG1, kappa) | specific for elephant PDPN | FACS, WB, IHC | PMab-295 epitope |
done |
Ab.antibody |
ferret podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-ferret PDPN mAb (PMab-241; mouse IgG2b, kappa) |
anti-bear PDPN mAb crossreacts with ferret PDPN | IHC, WB, FACS | PMab-241 | ||
anti-ferret PDPN mAb (PMab-292; mouse IgG1, kappa) |
specific for ferret PDPN | IHC, WB, FACS | PMab-292 epitope |
done |
Ab.antibody |
anti-ferret PDPN mAb (PMab-293; mouse IgM, kappa) |
specific for ferret PDPN | FACS, WB | |||
hamster podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-hamPDPN mAb (PMab-281; mouse IgG3, kappa) | specific for hamster PDPN | FACS, IHC | PMab-281
epitope |
done | |
anti-hamPDPN mAb (281-mG2a; mouse IgG2a, kappa) | specific for hamster PDPN; IgG2a version of PMab-281 | FACS, IHC |
281-mG2a
epitope |
done | |
anti-hamPDPN mAb (281-mG2a-f; mouse IgG2a, kappa) | defucocylated 281-mG2a | isotype control of mouse IgG2a in vivo |
H2Mab-214 H2Mab-77 |
done | |
giraffe podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-girPDPN mAb (PMab-301; mouse IgG1, kappa) | specific for giraffe PDPN Kd: 1.3 x 10-8 M |
FACS, WB, IHC | PMab-301 | ||
panda podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-panPDPN mAb (PMab-314; mouse IgG1, kappa) | specific for panda PDPN Kd: 1.3 x 10-8 M |
FACS, WB | PMab-314 | ||
rhinoceros podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-rhiPDPN mAb (PMab-315; mouse IgG2a, kappa) | specific for rhinoceros PDPN | FACS, WB | Ubukata et al | ||
hippopotamus podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-hipPDPN mAb (PMab-316; mouse IgG, kappa) | specific for hippopotamus PDPN | FACS, WB | Yamamoto et al | ||
anti-hipPDPN mAb (PMab-317; mouse IgG1, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
anti-hipPDPN mAb (PMab-318; mouse IgG1, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
anti-hipPDPN mAb (PMab-319; mouse Ig3(2b), kappa) | specific for hippopotamus PDPN | FACS, WB | |||
anti-hipPDPN mAb (PMab-320; mouse IgG1, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
anti-hipPDPN mAb (PMab-321; mouse IgM, kappa) | specific for hippopotamus PDPN | FACS | |||
anti-hipPDPN mAb (PMab-322; mouse Ig2a, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
anti-hipPDPN mAb (PMab-323; mouse IgM, kappa) | specific for hippopotamus PDPN | FACS |
ATRX | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-ATRX mAb (AMab-6; mouse IgG1, kappa) |
specific for human ATRX | IHC, WB | AMab-6 AMab-6_epitope AMab-6_IHC |
done | APRO abcam |
DGK | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-DGKalpha mAb (DaMab-2; mouse IgG1, kappa) |
specifi for DGKalpha | ICC | DaMab-2 epitope |
done | |
anti-DGKalpha mAb (Da2mG2a; mouse IgG2a, kappa) |
specifi for DGKalpha | ICC | done | ||
anti-DGKalpha mAb (DaMab-8; mouse IgG1, kappa) |
specific for DGKalpha | IHC | DaMab-8 |
done | |
anti-DGKalpha mAb (Da8mG2a; mouse IgG2a, kappa) |
specific for DGKalpha | ICC, IHC |
|
done | |
anti-DGKgamma mAb (DgMab-6; mouse IgG1, kappa) |
specific for DGKgamma | ICC | DgMab-6 |
done | |
anti-DGKalpha mAb (Dg6mG2a; mouse IgG2a, kappa) |
specifi for DGKgamma | ICC | done | ||
anti-DGKzeta mAb (DzMab-1; rat IgG2b, kappa) |
specific for DGKzeta | ICC |
DzMab-1 epitope |
done | |
anti-DGKzeta mAb (Dz1mG2a; mouse IgG2a, kappa) |
specific for DGKzeta | ICC | done | ||
anti-DGKeta mAb (DhMab-1;mouse IgG2c, kappa) |
specific for DGKeta | IHC | DhMab-1 | done | |
anti-DGKalpha mAb (Dh1mG2a; mouse IgG2a, kappa) |
specifi for DGKeata | ICC | done | ||
anti-DGKeata mAb (DhMab-4; mouse IgG2b, kappa) |
specific for DGKeta | IHC |
DhMab-4 ICC |
done | |
anti-DGKalpha mAb (Dh4mG2a; mouse IgG2a, kappa) |
specifi for DGKeata | ICC | done | ||
anti-DGKdelta mAb (DdMab-1; mouse IgG2c, kappa) |
specific for DGKdeta | IHC | DdMab-1 | done | |
anti-DGKalpha mAb (Dd1mG2a; mouse IgG2a, kappa) |
specifi for DGKdelta | ICC | done |
IDH | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-IDH1-R132H mAb (HMab-1; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-1 | done | APRP;
Merck
MBL; IBL; Sigma |
anti-IDH1-R132H mAb (HMab-2; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-2 | done | abcam |
anti-IDH1-R132S mAb (SMab-1; mouse IgG1, kappa) | specific for IDH1-R132S | IHC, WB | SMab-1 | done |
APRO;
abcam
IBL; MBL Merck_Sigma |
anti-IDH1-R132G mAb (GMab-r1; rat IgG2a, kappa) | specific for IDH1-R132G | IHC, WB | GMab-r1 | done |
abcam MBL |
anti-IDH2-R172K mAb (KMab-1; rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB isotype control of rat IgG2b |
KMab-1 | done | abcam MBL |
anti-IDH2-R172M mAb (MMab-1; rat IgG2b, kappa) | specific for IDH2-R172M | IHC, WB | MMab-1 | done |
abcam |
anti-IDH2-R172W mAb (WMab-1; rat IgG2b, kappa) | specific for IDH2-R172W | IHC, WB | WMab-1 | done |
abcam MBL |
anti-IDH2-R172S mAb (SMab-2; mouse IgG1, kappa) | specific for IDH2-R172S | IHC, WB | SMab-2 | done | abcam |
anti-IDH1 mAb (RMab-3; mouse IgG1, kappa) | specific for IDH1 | IHC, WB | RMab-3 | done |
BD MBL |
anti-IDH1 mAb(RcMab-1; rat IgG2a, kappa) | specific for IDH1 | IHC, WB isotype control of rat IgG2a |
RcMab-1 | done |
abcam CST MBL |
anti-IDH2 mAb (RMab-22; mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | RMab-22 | done | MBL |
anti-IDH2 mAb (KrMab-3; mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | KrMab-3 | done | CST BioLegend MBL |
anti-mIDH1/2 mAb (MsMab-1; mouse IgG1, kappa) | specific for mutated IDH1/2 | IHC, WB (ref) |
TJEM Brain Tumor Pathol Cancer Med |
done | abcam Merck |
anti-mIDH1/2 mAb (MsMab-2; rat IgG2a, kappa) | specific for mutated IDH1/2 | IHC, WB | MsMab-2 | done | MBL |
TERT | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mTERT mAb (TmMab-1; rat IgG1, kappa) |
specific for mTERT | ELISA, WB isotype control of rat IgG1 |
done | ||
anti-mTERT mAb (TmMab-2; rat IgG2a, kappa) |
specific for mTERT | ELISA isotype control of rat IgG2a |
done | ||
anti-mTERT mAb (TmMab-3; rat IgG1, kappa) |
specific for mTERT | ELISA, WB | done | ||
anti-mTERT mAb (TmMab-4; rat IgG1, kappa) |
specific for mTERT | ELISA | done | ||
anti-hTERT mAb (TpMab-1; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-1
(press) NCB |
done | |
anti-hTERT mAb (TpMab-2; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA | done | ||
anti-hTERT mAb (TpMab-3; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-3 (press)
NCB |
done | Merck |
anti-hTERT mAb (TpMab-35; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | ICC, WB, ELISA | TpMab-35 | ||
anti-hTERT mAb (TwMab-1; mouse IgG1, kappa) |
specific for hTERT | IHC, WB, ELISA | TwMab-1 | done | Merck |
anti-hTERT mAb (TMab-6; mouse IgM, kappa) |
specific for hTERT | IHC |
TMab-6 TMab-6_epitope |
done |
SARS-CoV-2 (S1 RBD) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 S1-RBD mAb (CvMab-1; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 319-338 aa RBD: Receptor binding domain |
ELISA,WB, IHC | done | ||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-2; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-3; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 469-478 aa |
ELISA,WB, IHC, neutralization | |||
anti SARS-CoV-2 S1-RBD mAb (CvMab-6; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | CvMab-6 | done | |
anti-SARS-CoV-2 S1-RBD mAb (CvMab-7; mouse IgM, kappa) |
specific for SARS-CoV-2 S1-RBD epitope:459-478 aa |
ELISA, WB, IHC, neutralization | done | ||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-13; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC | done | ||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-17; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, neutralization, IHC | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-18; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, neutralization, IHC | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-24; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-25; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, IHC, WB |
SARS-CoV-2 (S1 N terminus) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-32; mouse IgG2b, kappa) |
specific for SARS-CoV-2 S1N terminus | ELISA, IHC, WB |
SARS-CoV-2 (S2) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-36; mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA, WB | |||
anti-SARS-CoV-2 mAb (CvMab-62; mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA isotype control of mouse IgG1 |
CvMab-62 | done | |
anti-SARS-CoV-2 mAb (CvMab-6-Fab; mouse Fab, kappa) |
specific for SARS-CoV-2 S2 | ELISA | done | ||
anti-SARS-CoV-2 mAb (humCvMab-62; human IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA isotype control of human IgG1 |
done |
SARS-CoV-2 (bi-specific) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-bis1) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-H_CvM62scFv |
CvMab-bis1 | done | ||
anti-SARS-CoV-2 mAb (CvMab-bis2) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-L_CvM62scFv |
CvMab-bis2 | done | ||
anti-SARS-CoV-2 mAb (CvMab-bis3) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-62-H_CvM6scFv |
CvMab-bis3 | done | ||
anti-SARS-CoV-2 mAb (CvMab-bis4) |
specific for SARS-CoV-2 S1+S2
bispecific mAb CvMab-62-L_CvM6scFv |
CvMab-bis4 | done | ||
CvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | Bebtelovimab | done | ||
humCvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | Bebtelovimab | done | ||
CvMab-62-H_Cilgavimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | done |
SARS-CoV-2 (humanized) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
Bebtelovimab (human IgG1, lambda) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; weak activity for all variants | Bebtelovimab | done | |
Cilgavimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Cilgavimab plus tixagevimab (EVUSHELD) |
Neutralization; weak activity for BA.2; resistant for BA.4/5 | done | ||
Casirivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Casirivimab plus imdevimab (Ronapreve) |
Neutralization; weak activity for Omicron | done | ||
Bamlanivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; no activity for Omicron | done | ||
Bebtelovimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | Bebtelovimab | done | ||
Cilgavimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | done |
RdRP | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-RdRP mAb (RdMab-2; mouse IgG2a, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV | ELISA, WB, IP, ICC | RdMab-2 | done | |
anti-RdRP mAb (RdMab-13; mouse IgM, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB isotype control of mouse IgM |
RdMab-13 | done | |
anti-RdRP mAb (RdMab-15; mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-15 | ||
anti-RdRP mAb (RdMab-16; mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-16 | ||
anti-RdRP mAb (RdMab-20; mouse IgG2b, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB isotype control of mouse IgG2b |
RdMab-20 | done |
dog PDPN | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
dog EGFR | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (134-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR Osteosarcoma Fibroblastic Mammary |
done | |
anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
dog HER2 | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done | |
anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
EGFR-HER2 (bispecific) | Character | Application | Ref | Gene cloning | Company |
anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 | FACS, IHC | done | ||
anti-dog PD-L1 mAb (L1Mab-348; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-349; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-350; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-351; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
anti-dog PD-L1 mAb (L1Mab-353; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done | |
anti-dog PD-L1 mAb (L1Mab-355; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-356; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA |
cat MET | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-cat MET mAb (cMMab-1; mouse IgG1, kappa) |
specific for cat MET (No. 43) | FACS | done | ||
anti-cat MET mAb (cMMab-2; mouse IgG1, kappa) |
specific for cat MET (No. 46) | FACS | done | ||
anti-cat MET mAb (cMMab-3; mouse IgG1, kappa) |
specific for cat MET (No. 62) | FACS | done | ||
anti-cat MET mAb (cMMab-4; mouse IgG1, kappa) |
specific for cat MET (No. 63) | FACS | done | ||
anti-cat MET mAb (cMMab-5; mouse IgG1, kappa) |
specific for cat MET (No. 102) | FACS | |||
anti-cat MET mAb (cMMab-6; mouse IgG1, kappa) |
specific for cat MET (No. 106) | FACS | |||
anti-cat MET mAb (cMMab-7; mouse IgG1, kappa) |
specific for cat MET (No. 115) | FACS | |||
anti-cat MET mAb (cMMab-8; mouse IgG1, kappa) |
specific for cat MET (No. 116) | FACS | |||
anti-cat MET mAb (cMMab-9; mouse IgG1, kappa) |
specific for cat MET (No. 126) | FACS | |||
anti-cat MET mAb (cMMab-10; mouse IgG1, kappa) |
specific for cat MET (No. 173) | FACS | done | ||
cat podoplanin | Character | Application | Ref | Gene cloning | Company |
anti-cat PDPN mAb (PMab-52; mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
done | zenogen |
anti-tiger PDPN mAb (PMab-231; mouse IgG2a, kappa) |
crossreact with cat PDPN | IHC, WB, FACS | PMab-231 epitope; lion |
done | zenogen |
anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) |
defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
PDPN | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab; patent | IHC, WB, FACS | PDPN_review LpMab-2 |
done | restricted |
anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab |
IHC, WB, FACS | LpMab-23 IHC patent |
done | restricted |
anti-hPDPN mAb (PMab-117; rat IgM, kappa) | CasMab | FACS | Cells2022 patent |
done | restricted |
PDPN | Character | Application | Ref | Gene cloning | Company |
anti-human PDPN mAb(chLpMab-2; human IgG1, kappa) |
CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2 | IP, IHC, WB, FACS | chLpMab-2 | done | restricted |
anti-human PDPN mAb (chLpMab-23; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23 | IHC, WB, FACS | chLpMab-23 | done | restricted |
anti-human PDPN mAb (humLpMab-23-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from LpMab-23 |
IHC, WB, FACS | humLpMab-23-f | done | restricted |
anti-human PDPN mAb (chPMab-117; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from PMab-117 | FACS | done | restricted | |
anti-human PDPN mAb (humPMab-117-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from PMab-117 | FACS | done | restricted |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab
|
FACS | PcMab-6 patent |
done | restricted |
anti-PODXL mAb (PcMab-60; mouse IgM, kappa) |
anti-PODXL CasMab | FACS | PcMab-60 epitope patent |
done | restricted |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
anti-PODXL mAb (PcMab-6-mG2a-f; mouse IgG2a) |
anti-PODXL CasMab; IgG2a version of PcMab-6
|
FACS, ADCC/CDC | PcMab-6-mG2a-f | done | restricted |
anti-PODXL mAb (PcMab-6-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-6 | FACS, ADCC/CDC | done | restricted | |
anti-PODXL mAb (humPcMab-6-f; human IgG1) |
CasMab for PODXL; humanized mAb originated from PcMab-6
|
FACS | humPcMab-6-f | done | restricted |
anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa) |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | 60-mG2a | done | restricted |
anti-PODXL mAb (60-mG2a-f; mouse IgG2a, kappa) |
anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60 | FACS, ADCC/CDC, antitumor activities | 60-mG2a-f | done | restricted |
anti-PODXL mAb (PcMab-60-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-60 | FACS, ADCC/CDC | done | restricted | |
anti-PODXL mAb (humPcMab-60; human IgG1) |
anti-PODXL CasMab; humanized PcMab-60 | FACS, ADCC/CDC | done | restricted |
CD44s | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44s mAb (C44Mab-1012; mouse IgM, kappa) |
Mab1 for CD44s (exon-6) cossreact with mouse CD44 |
FACS | done | ||
anti-CD44s mAb (C44Mab-1075; mouse IgG2a, kappa) |
Mab2 for CD44s (exon-6) | FACS | done | ||
anti-CD44s mAb (C44Mab-1095; mouse IgG1, kappa) |
Mab3 for CD44s (exon-6) | FACS | done | ||
CD44s | Character | Application | Ref | Gene cloning | Company |
anti-CD44s mAb (C44Mab-1012-mG1; mouse IgG1) |
Mab1 for CD44s (exon-6) | FACS | done | ||
anti-CD44s mAb (C44Mab-1012-hG1; human IgG1) |
Mab1 for CD44s (exon-6) | FACS | done |
CD44v3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44v3 mAb (C44Mab-1080; mouse IgG1, kappa) |
Mab6 for CD44v3 | FACS, WB, IHC | done | ||
anti-CD44v3 mAb (C44Mab-1006; mouse IgG1, kappa) |
Mab11 for CD44v3 | FACS, WB, IHC | done | ||
CD44v5 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v5 mAb (C44Mab-1088; mouse IgG1, kappa) |
Mab8 for CD44v5 | FACS, WB, IHC | done | ||
anti-CD44v5 mAb (C44Mab-1003; mouse IgG1, kappa) |
Mab12 for CD44v5 | FACS, WB, IHC | done | ||
CD44v6 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa) |
V6CasMab-1 (IgM) for CD44v6 | FACS, WB, IHC | done | restricted | |
anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa) |
V6CasMab-2 for CD44v6 | FACS, WB, IHC | done | restricted | |
anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa) |
V6CasMab-3 for CD44v6 | FACS, WB, IHC | done | restricted | |
anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa) |
V6CasMab-4 (IgM) for CD44v6 | FACS, WB, IHC | done | restricted | |
anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa) |
V6CasMab-5 (IgG3) for CD44v6 | FACS, WB, IHC | done | restricted | |
CD44v6 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v6 mAb (C44Mab-1074-mG1; mouse IgG1, kappa) |
V6CasMab-1 for CD44v6 | FACS, WB, IHC | restricted | ||
anti-CD44v6 mAb (C44Mab-1089-mG1; mouse IgG1, kappa) |
V6CasMab-4 for CD44v6 | FACS, WB, IHC | restricted | ||
anti-CD44v6 mAb (C44Mab-1092-mG1; mouse IgG1, kappa) |
V6CasMab-5 for CD44v6 | FACS, WB, IHC | restricted | ||
CD44v7 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v7 mAb (C44Mab-1030; mouse IgM, kappa) |
Mab4 for CD44v7 | FACS, WB, IHC | done | ||
anti-CD44v7 mAb (C44Mab-1048; mouse IgG1, kappa) |
Mab5 for CD44v7 | FACS, WB, IHC | done | ||
anti-CD44v7 mAb (C44Mab-1034; mouse IgG1, kappa) |
Mab10 for CD44v7 | FACS, WB, IHC | done |
EpCAM | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EpCAM mAb (EpMab-1147; mouse IgG1, kappa) |
Mab3 for EpCAM | FACS | done | ||
anti-EpCAM mAb (EpMab-1007; mouse IgG1, kappa) |
Mab4 for EpCAM | FACS | done | ||
anti-EpCAM mAb (EpMab-1013; mouse IgG1, kappa) |
Mab5 for EpCAM | FACS | done | ||
anti-EpCAM mAb (EpMab-1022; mouse IgG1, kappa) |
Mab6 for EpCAM | FACS | done | ||
anti-EpCAM mAb (EpMab-1069; mouse IgG1, kappa) |
Mab7 for EpCAM | FACS | done |
TROP2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TROP2 mAb (TrMab-1100; mouse IgG1, kappa) |
Mab1 for human TROP2 | FACS | done | ||
anti-TROP2 mAb (TrMab-1148; mouse IgG1, kappa) |
Mab3 for human TROP2 | FACS | done | ||
anti-TROP2 mAb (TrMab-1156; mouse IgG2b, kappa) |
Mab4 for human TROP2 | FACS | done |
EGFR | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb (ECasMab-1001; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1002; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1003; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1004; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1005; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1006; mouse IgM, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1007; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1008; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1009; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1010; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1011; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1012; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1013; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1014; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1015; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1016; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1017; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1018; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1019; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
anti-EGFR mAb (ECasMab-1020; mouse IgM, kappa) |
specific for EGFR | FACS | done | restricted |
HER2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2CasMab-1; mouse IgG1,kappa) |
H2Mab-214; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-214 | done | restricted |
anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa) |
H2Mab-250; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
anti-HER2 mAb (H2CasMab-3; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-4; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-5; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-6; mouse IgG2a,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-7; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-8; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-9; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-10; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-11; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-12; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-13; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-14; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-15; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-16; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-17; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-18; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-19; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-20; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-21; mouse IgG2a,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-22; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
anti-HER2 mAb (H2CasMab-23; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
HER2 | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-250-mG2af; mouse IgG2a,kappa) |
H2CasMab-2; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
anti-HER2 mAb (H2Mab-250-hG1-f; human IgG1,kappa) |
H2CasMab-2; specific for HER2; domain-IV | ADCC/CDC; antitumor activities | 250_in vivo 250_CDC |
done | restricted |
anti-HER2 mAb (humH2Mab-250-f; human IgG1,kappa) |
humanized H2Mab-250; H2CasMab-2; specific for HER2; domain-IV | ADCC/CDC; antitumor activities | done | restricted | |
anti-HER2 mAb (H2Mab-214-mG2af; mouse IgG2a,kappa) |
H2CasMab-1; specific for HER2; domain-IV | FACS, WB, IHC | 214-mG2a-f | done | restricted |
anti-HER2 mAb (H2Mab-214-hG1; human IgG1,kappa) |
H2CasMab-1; specific for HER2; domain-IV | FACS, WB, IHC | done | restricted |
HER3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti HER3 mAb (H3Mab-1059; mouse IgG1,kappa) |
Mab1 for HER3 | FACS | done | ||
anti HER3 mAb (H3Mab-1170; mouse IgG1,kappa) |
Mab2 for HER3 | FACS | done |
mouse EGFR | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb (EMab-1302; rat IgG1, lambda) | crossreact with human EGFR; domain-I
semi-candidate |
FACS | |||
anti-EGFR mAb (EMab-1303; rat IgM, kappa) | crossreact with human EGFR; domain-III
candidate |
FACS | |||
anti-EGFR mAb (EMab-1304; rat IgG1, lambda) | crossreact with human EGFR; domain-I
semi-candidate |
FACS | |||
mouse EGFR | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-1303-mG1; mouse IgG1, kappa) | mouse IgG1 type of EMab-1303 | FACS | |||
anti-EGFR mAb (EMab-1303-mG2a; mouse IgG2a, kappa) | mouse IgG2a type of EMab-1303 | FACS | |||
anti-EGFR mAb (EMab-1303-hG1; human IgG1, kappa) | humna IgG1 type of EMab-1303 | FACS |
mouse HER2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-1301; rat IgG2a, lambda) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
anti-HER2 mAb (H2Mab-1316; rat IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
anti-HER2 mAb (H2Mab-1319; rat IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-1301-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1301;
cross-react with HER2 (human) |
FACS | ongoing | ||
anti-HER2 mAb (H2Mab-1316-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1316; cross-react with HER2 (human) |
FACS | ongoing | ||
anti-HER2 mAb (H2Mab-1319-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1319; cross-react with HER2 (human) |
FACS | ongoing |
CD19 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD19 mAb (C19Mab-2; mouse IgG1,kappa) | specific for CD19; CBIS method; LN229/CD19 immunization | FACS | done | restricted | CD19 | Character | Application | Ref | Gene cloning | Company |
anti-CD19 mAb (humC19Mab-2 -scFv) |
scFv of humanized C19Mab-2 | FACS | done | restricted |
GPC3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-GPC3 mAb (G3Mab-1; mouse IgG1, kappa) |
specific for human GPC3 ref: abcam |
FACS | done | restricted | |
anti-GPC3 mAb (G3Mab-2; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | restricted | |
anti-GPC3 mAb (G3Mab-3; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | restricted | |
anti-GPC3 mAb (humG3Mab-1; human IgG1, kappa) |
specific for human GPC3 | FACS | done | restricted | |
anti-GPC3 mAb (humG3Mab-2; human IgG1, kappa) |
specific for human GPC3 | FACS | done | restricted | |
anti-GPC3 mAb (humG3Mab-3; human IgG1, kappa) |
specific for human GPC3 | FACS | done | restricted | |
GPC3 | Character | Application | Ref | Gene cloning | Company |
anti-GPC3 mAb (humG3Mab-1-scFv-Fc) |
specific for human GPC3 | CAR-T | done | restricted | |
anti-GPC3 mAb (humG3Mab-2-scFv-Fc) |
specific for human GPC3 | CAR-T | done | restricted | |
anti-GPC3 mAb (humG3Mab-3-scFv-Fc) |
specific for human GPC3 | CAR-T | done | restricted |
HER2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa) |
H2Mab-250; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
HER2 | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2CasMab-2-scFv-Fc) |
specific for HER2; domain-IV |
CART | FT825 | done | restricted |
PDPN | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
done | restricted |
anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab |
IHC, WB, FACS | LpMab-23 IHC patent |
done | restricted |
anti-hPDPN mAb (PMab-117; rat IgM, kappa) | CasMab | FACS | Cells2022 patent |
done | restricted |
PDPN | Character | Application | Ref | Gene cloning | Company |
anti-hPDPN mAb (LpMab-2-scFv-Fc) | CasMab for human PDPN; scFv originated from LpMab-2 |
CART | LpMab-2-CART | done | restricted |
anti-hPDPN mAb (humLpMab-23-scFv-Fc) | CasMab for human PDPN; scFv originated from LpMab-23 |
CART | in preparation | done | restricted |
anti-hPDPN mAb (humPMab-117-scFv-Fc) | CasMab for human PDPN; scFv originated from PMab-117 |
CART | done | restricted |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab | FACS | PcMab-6 patent |
done | restricted |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
anti-hPDPN mAb (humPcMab-6-scFv; scFv) | CasMab; scFv originated from PcMab-6 | CART | in preparation | done | restricted |